PAVmed (PAVM) Prices Additional $8.1 Million Common Stock Registered Direct Offering

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of approximately 5.1 million shares of common stock in a registered direct offering with predominantly existing institutional investors at a price of $1.60 per share for gross proceeds of $8.1 million.

The estimated net proceeds to PAVmed from the registered direct offering are expected to be approximately $7.4 million after deducting the placement agents’ fees and other estimated offering expenses. The offering is expected to close on or about December 22, 2020 subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the lead placement agent and Lake Street Capital Markets LLC is acting as co-placement agent in connection with the offering.

You May Also Be Interested In

• QNB Corp. overallotment option adds 160,714 shares at $42 each
• ESS Tech launches $3.2M stock offering at $0.50 per share
• Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders